Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lea Trela-Larsen

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Acta Orthopaedica|June 1, 2017
Preoperative psychosocial risk factors for poor outcomes at 1 and 5 years after total knee replacementVikki Wylde, Lea Trela-Larsen, Michael R Whitehouse, et al.
International Journal of Technology Assessment in Health Care|July 11, 2022
Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysisNiamh Carey, Joy Leahy, Lea Trela-Larsen, et al.
Journal of Market Access & Health Policy|January 23, 2023
Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare settingNiamh Carey, Joy Leahy, Lea Trela-Larsen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 1, 2021
Estimating the Theoretical Cost Implications of Funding New Drugs Considered Not to Be Cost-EffectiveCormac Kennedy, Laura McCullagh, Roisin Adams, et al.
Sexually Transmitted Infections|October 2, 2012
Chlamydia screening, retesting and repeat diagnoses in Cornwall, UK 2003-2009Katy M E Turner, Paddy J Horner, Lea Trela-Larsen, et al.
Acta Orthopaedica|October 27, 2017
The association between cement type and the subsequent risk of revision surgery in primary total hip replacementLea Trela-Larsen, Adrian Sayers, Ashley William Blom, et al.
International Journal of Environmental Research and Public Health|April 30, 2021
Understanding the Challenges and Uncertainties of Seroprevalence Studies for SARS-CoV-2David McConnell, Conor Hickey, Norma Bargary, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 17, 2023
A Comparison of Relative-Efficacy Estimate(S) Derived From Both Matching-Adjusted Indirect Comparisons and Standard Anchored Indirect Treatment Comparisons: A Review of Matching-Adjusted Indirect ComparisonsOwen Cassidy, Marie Harte, Lea Trela-Larsen, et al.
Drug and Alcohol Dependence|June 26, 2017
Body mass index, body dissatisfaction and adolescent smoking initiationLaurence J Howe, Lea Trela-Larsen, Michelle Taylor, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 31, 2020
Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review GroupJoy Leahy, Conor Hickey, David McConnell, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Acta Orthopaedica|June 1, 2017
Preoperative psychosocial risk factors for poor outcomes at 1 and 5 years after total knee replacementVikki Wylde, Lea Trela-Larsen, Michael R Whitehouse, et al.
International Journal of Technology Assessment in Health Care|July 11, 2022
Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysisNiamh Carey, Joy Leahy, Lea Trela-Larsen, et al.
Journal of Market Access & Health Policy|January 23, 2023
Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare settingNiamh Carey, Joy Leahy, Lea Trela-Larsen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 1, 2021
Estimating the Theoretical Cost Implications of Funding New Drugs Considered Not to Be Cost-EffectiveCormac Kennedy, Laura McCullagh, Roisin Adams, et al.
Sexually Transmitted Infections|October 2, 2012
Chlamydia screening, retesting and repeat diagnoses in Cornwall, UK 2003-2009Katy M E Turner, Paddy J Horner, Lea Trela-Larsen, et al.
Acta Orthopaedica|October 27, 2017
The association between cement type and the subsequent risk of revision surgery in primary total hip replacementLea Trela-Larsen, Adrian Sayers, Ashley William Blom, et al.
International Journal of Environmental Research and Public Health|April 30, 2021
Understanding the Challenges and Uncertainties of Seroprevalence Studies for SARS-CoV-2David McConnell, Conor Hickey, Norma Bargary, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 17, 2023
A Comparison of Relative-Efficacy Estimate(S) Derived From Both Matching-Adjusted Indirect Comparisons and Standard Anchored Indirect Treatment Comparisons: A Review of Matching-Adjusted Indirect ComparisonsOwen Cassidy, Marie Harte, Lea Trela-Larsen, et al.
Drug and Alcohol Dependence|June 26, 2017
Body mass index, body dissatisfaction and adolescent smoking initiationLaurence J Howe, Lea Trela-Larsen, Michelle Taylor, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 31, 2020
Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review GroupJoy Leahy, Conor Hickey, David McConnell, et al.
Pageof 2